Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. announced financial results for its fiscal third quarter ended December 31, 2025, by issuing a press release on February 12, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Press release dated and issued on February 12, 2026, covering Q3 fiscal 2026 results (quarter ended December 31, 2025).
• The press release is furnished as Exhibit 99.1 to the Form 8-K (Item 2.02); the filing includes the standard disclaimer that the furnished information is not “filed” under the Exchange Act.
• The Form 8-K was signed by President and CEO Shawn K. Singh on February 12, 2026.
• The filing also includes Inline XBRL cover page data (Exhibit 104).

Why It Matters
This 8-K notifies investors that Vistagen has publicly released its latest quarterly financial results. Investors should review the furnished press release (Exhibit 99.1) for the company’s reported revenue, profit/loss, cash position, and any operational updates or guidance that could affect the stock. The filing’s “furnished, not filed” status means the press release is disclosed to the market but is not subject to certain Exchange Act liabilities.